- Trial phase
- Approved
- Time to market
- Approved but awaiting DEA scheduling before US dispensing (expected by November 2026); already launched in Japan and China (October 2026).
- Why 4/10
- Orzeyful is already FDA-approved (August 5, 2026) with no pending PDUFA or pivotal readout; the remaining near-term catalyst is the DEA scheduling decision expected by November 2026, a procedural step rather than a binary regulatory event. For a large diversified pharma like Takeda, this single drug drives limited share-price impact, scoring 4.
Watch for the DEA scheduling decision expected by November 2026, which will determine when Orzeyful can be dispensed in the US. Also watch Takeda's December 11, 2026 Capital Markets Day for peak-sales targets and Q3 brand growth. The stock is down ~1.9% today at $19.77 as of this report.
Price Chart
Executive Summary
Orzeyful (oveporexton, formerly TAK-861) is Takeda's first-in-class oral orexin receptor 2 (OX2R) agonist approved by the FDA on August 5, 2026 for narcolepsy type 1 in adults. It is the first drug to treat the underlying orexin deficiency rather than just symptoms. Two Phase 3 trials (FirstLight and RadiantLight) met all endpoints. The drug is also approved in China (July 2026) and Japan (October 2026), with launches underway in Japan and China. US commercial launch awaits DEA scheduling, expected by November 2026. Analysts project $2-3 billion peak sales for NT1 alone. For Takeda, a large diversified pharma, Orzeyful is one of many pipeline assets, limiting its single-drug impact on the stock.
How It Works
Orzeyful is an oral tablet that acts like a key to activate orexin receptors in the brain. Orexin is a natural chemical that promotes wakefulness; people with narcolepsy type 1 have lost the cells that produce orexin. By directly stimulating the orexin receptor, Orzeyful restores the brain's wake-up signal, addressing the root cause of the disease rather than just treating individual symptoms like sleepiness or muscle weakness.
Trial Status
Two Phase 3 trials (FirstLight NCT06470828 and RadiantLight NCT06505031) completed with all primary and secondary endpoints met. FDA approved August 5, 2026. Also approved in China July 2026 and Japan October 2026.
The Two-Sided Case
Upcoming Catalysts
- DEA scheduling decision expected by November 2026 for US commercial availability
- Takeda Capital Markets Day on December 11, 2026 with peak-sales targets
- Q3 fiscal 2026 earnings and brand growth
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report